GLP1R and aortic stenosis: Differences in myocardial GLP‐1 receptor expression may explain the varying dose–response of Ca transients to semaglutide between the human AS patients with a HFpEF‐like phenotype, which exhibited higher GLP‐1 receptor expression, and the end‐stage HFrEF patients.